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Abstract
Dengue virus produces a mild acute febrile illness, dengue fever (DF) and a severe illness, dengue hemorrhagic fever (DHF). The
characteristic feature of DHF is increased capillary permeability leading to extensive plasma leakage in serous cavities resulting in shock.
The pathogenesis of DHF is not fully understood. This paper presents a cascade of cytokines, that in our view, may lead to DHF. The main
feature is the early generation of a unique cytokine, human cytotoxic factor (hCF) that initiates a series of events leading to a shift from
Th1-type response in mild illness to a Th2-type response resulting in severe DHF. The shift from Th1 to Th2 is regulated by the relative
levels of interferon-gamma and interleukin (IL)-10 and between IL-12 and transforming growth factor-L, which showed an inverse
relationship in patients with DF. ß 2000 Published by Elsevier Science B.V. on behalf of the Federation of European Microbiological
Societies.
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1. Introduction
Dengue virus (DV) is transmitted through mosquito bite
and is prevalent in over 100 tropical and subtropical coun-
tries with about 2 000 000 000 people at risk [1]. DV infec-
tion is mostly asymptomatic or produces a mild self-limit-
ing acute febrile illness, dengue fever (DF). It can also
produce a life threatening severe illness, dengue hemorrha-
gic fever (DHF) with minor or major bleeding from di¡er-
ent sites [2]. DHF has emerged as the most important
arbovirus disease in man in the last two decades. It has
been estimated that about 50^100 000 000 cases of DF oc-
cur every year with about 250 000 to 500 000 cases of DHF
[3]. DHF has been classi¢ed into four grades on the basis
of the clinical presentation and laboratory ¢ndings: the
mildest is grade I and the most severe is grade IV. The
pathognomonic features of DHF are increased capillary
permeability without morphological damage to the capil-
lary endothelium (only the cell junctions are opened up),
altered number and functions of leucocytes, increased
hematocrit and thrombocytopenia [4^6]. Extensive plasma
leakage in various serous cavities of the body including the
pleural, pericardial and peritoneal cavities in DHF grades
III and IV may result in profound shock, the dengue
shock syndrome (DSS). Despite extensive studies, the
pathogenesis of DHF is still not fully understood. Various
mechanisms that have been considered include, immune
complex disease, enhancing antibodies, complement and
its products, various soluble mediators including cytokines
and virus virulence etc. (reviewed in [6^8]). In this paper
we present a brief review of the cytokines that have been
studied in patients with dengue disease and have organized
them in a cascade to explain our view on the pathogenesis
of DHF.
2. Th1 and Th2 cytokines in patients with dengue
Cytokine secretion pro¢les distinguish helper T (Th) 1
and Th2 cells, which are the major subsets of fully, di¡er-
entiated CD4 Th cells. Th1 cells secrete interferon-gam-
ma (IFN-Q), interleukin-2 (IL-2) and tumor necrosis fac-
tor-L (TNF-L) and are responsible for cell-mediated
in£ammatory reactions, delayed type hypersensitivity, tis-
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sue injury in infections and autoimmune diseases. Th2
cells secrete IL-4, IL-5, IL-6, IL-10, and IL-13 (Fig. 1)
and are associated with help for B cell antibody produc-
tion. Cross-regulation of Th1 and Th2 is primarily medi-
ated by IL-10 and IFN-Q respectively (Fig. 1). Infections
eliciting a dominant humoral immune response induce a
higher expression of Th2-related cytokines, whereas those
characterized by delayed-type hypersensitivity response
show a higher expression of Th1 cytokines. In a number
of parasitic, fungal, bacterial and viral infections such as
human immunode¢ciency virus, herpes simplex and in£u-
enza viruses, a Th1 response is linked to recovery from
infection while a Th2-type response tends to lead to severe
pathology and exacerbation of the disease (reviewed in
[9]).
With regard to dengue disease, the most signi¢cant ¢nd-
ing of our recent study is a shift from the predominant
Th1-type response observed in cases of DF to the Th2-
type in severe cases of DHF grade IV (Table 1). Increased
serum levels of IL-4, IL-6 and IL-10 were observed mainly
in cases of DHF grades III and IV. In contrast, the levels
of IFN-Q and IL-2 were highest in cases of DF and low in
DHF grade IV. TNF-K levels did not show a de¢nite
associative pattern with DF or DHF. The cytokine levels
to increase ¢rst were IL-2, IL-6, IFN-Q and TNF-K while
IL-4, and IL-10 tended to emerge during days 4^8 of the
illness [10]. The data were analyzed to ascertain whether
the cytokine response in individual patients could be cate-
gorized as Th1-biased, Th2-biased or indeterminate (i.e.
having a mixed response). The cytokine pro¢le of individ-
ual patients with DF showed increased levels of IFN-Q and
IL-2 and absence of IL-4, IL-6 and IL-10, a typical Th1-
type response while that of DHF grade IV showed in-
creased levels of IL-4, IL-6 and IL-10 and lower levels
or absence of IL-2 and IFN-Q, a typical Th2-type response
(Table 1). An analysis of total cases showed that 66% of
the cases of DF had Th1-type response. As the severity of
the illness increased, the response shifted to Th2-type in
71% of the cases of DHF grade IV [10]. The serum levels
of IL-13 followed the typical pattern of Th2-type cyto-
kines, being absent in patients with DF and the highest
levels in cases of DHF grade IV (unpublished results).
In a follow-up study, we investigated the sequence of
appearance of Th1- and Th2-type cytokines in human pe-
ripheral blood leucocytes of healthy donors infected in
vitro with DV [11]. The cytokines that appeared in the
culture supernatants on the ¢rst day post-infection (p.i.)
were human cytotoxic factor (hCF), TNF-K, IL-2 and IL-
6; their levels reached a peak on the second day. IFN-Q
appeared on the 2nd day with a peak on the 3rd day. The
levels of these cytokines declined quickly except hCF and
IL-2. The cytokines that appeared later were IL-10 and
Fig. 1. DV-induced cytokine cascade. DV replicates in macrophage and is presented to recruit CD4 cells which produce hCF. hCF induces a cytokine
cascade that may lead to Th1-type response causing a mild illness, the DF or to a Th2-type response resulting in various grades of severe illness, the
DHF. Thin line, positive induction; Interrupted line, inhibition; Thick line, damaging e¡ect.
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IL-5 on the 4th day and IL-4 on the 6th day p.i. DV
replicated in the peripheral blood leucocyte cultures and
was present throughout the course of the study. The ¢nd-
ings of this study showed that DV induced a predominant
Th1-type cytokine response during the ¢rst three days of
infection of peripheral blood leucocytes in vitro which was
replaced by a Th2-type response later [11].
3. Proin£ammatory cytokine in patients with dengue
Non-Th1 and Th2 cytokines include IL-1, IL-6 and
TNF-K. They play a signi¢cant role in the development
of acute in£ammatory responses. The levels of IL-1L have
been studied in patients with dengue (Table 1) and were
found to be similar to those of normal healthy controls
[12^16]. Although higher levels of TNF-K and IL-6 have
been reported in patients with dengue (Table 1) a de¢nite
association with the severity of illness was not found
[10,12^14,17^20].
4. Macrophage cytokines in patients with dengue
4.1. IL-8:
Elevated levels of IL-8 have been shown in several viral
infections, including dengue [21]. We have shown that in-
creased levels of IL-8 in the sera and IL-8-mRNA in the
PBMC are associated with the increasing severity of DHF.
About half of the patients of DHF grade IV who died had
serum levels of IL-8 above 200 pg ml31, the highest being
5568 pg ml31 in one of them. These results suggest that
IL-8 might have an important role in increasing the se-
verity of the disease and death [21]. The intravascular
coagulopathy seen in DHF [4] may be attributable, at least
in part, to the e¡ects of IL-8. High local IL-8 levels are
also associated with pleural e¡usion [22]. It is tempting to
associate the increased vascular permeability with leakage
of plasma in DHF with the presence of high levels of IL-8,
and it may also be a useful indicator of serious outcome of
DF.
4.2. IL-12
IL-12 has a profound e¡ect on the upregulation of Th1
cells and Th1-type cytokines, while its absence shifts the
balance towards Th2-type cytokines. IL-12 has been asso-
ciated with clearance of virus, host recovery and protec-
tion in a large number of viral infections (reviewed in
[23,24]). Elevated levels of IL-12 were seen in the patients
with milder DF and complete absence in the patients with
DHF grades III and IV (Table 1) [25]. Thus IL-12 might
play a role in preventing the severe dengue disease by
maintaining the Th1-type response. If this is true, IL-12
therapy could have a profound bene¢cial e¡ect on the
outcome of severe dengue disease as is seen in a number
of other viral infections (reviewed in [24]).
4.3. IL-18:
IL-18 was ¢rst identi¢ed as a costimulatory factor for
the production of IFN-Q following endotoxin shock. It is
produced by activated macrophages and a variety of other
cells. It has structural homology with the IL-1 family and
shares with IL-12 the function of inducing Th1 cells to
produce IFN-Q (reviewed in [26]). In dengue, IL-18 was
present in 40% of the patients with mild illness. The pos-
itivity increased with the increasing severity of the illness
and was highest (80%) in patients with DHF grade IV
(unpublished results). This is unlike IL-12, which was
high in DF and absent in patients with DHF grades III
and IV and is contrary to expectation, as all the Th2-type
cytokines are high in DHF grade IV patients (Table 1). A
recent study has shown that IL-18 is a potent co-inducer
of IL-13 in NK and T cells, and depending upon the cell
type, it can act as a strong coinducer of Th1 or Th2 cy-
tokines [27]. This could explain its role in dengue.
4.4. Transforming growth factor-L1 (TGF-L1)
TGF-L has multiple immunomodulatory e¡ects on var-
ious target cells. TGF-L1 may act as a proin£ammatory or
anti-in£ammatory cytokine depending upon its concentra-
tion. In the acute phase it induces secretion of IL-1K and
TNF-K to control the infection; however, TGF-L also
decreases the production of free radicals, inhibits receptor
expression and functions of IFN-Q, IL-1K, IL-2 and TNF-
K, inhibiting Th1-type cytokines and enhancing produc-
tion of Th2-type cytokines such as IL-10 (reviewed in
[28]). In patients infected with DV, both the severity of
disease and the duration of illness were correlated with the
level of TGF-L1, i.e., the maximum levels of TGF-L1 were
detected in patients with DHF grade IV (Table 1) and
those who have the disease for more than 9 days [29].
Table 1
Cytokines levels in patients with dengue
Cytokines DF DHF References
IL-1L C C [12^16]
IL-2 uu u [10,43]
IL-4 s uu [10]
IL-6 u uu [10,12^14,16]
IL-8 s uu [20,44]
IL-10 s uu [10,45]
IL-12 uu s [25]
IL-13 s uu Personal unpublished data
IL-18 u uu Personal unpublished data
TNF-K uu uu [10,12,16^20]
IFN-Q uu u [10,43]
TGF-L s uu [15,29]
hCF u uu [30,31,32,36]
C, no change; s, decrease; u, increase; uu, marked increase.
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The only other cytokine to show such high positivity in
patients with dengue is hCF which is also associated with
the severity of the illness. [5,10,30^32]. The results of se-
rum levels of TGF-L1 and IL-12, when analyzed together,
showed an inverse relationship in patients with DF and
with various grades of DHF [25].
5. hCF in patients with dengue
The macrophage is the principal cell to replicate DV
and is obligatory for the presentation of its antigen
[34,35]. This recruits CD4 cells that produce a unique
cytokine, CF, in mice (mCF) and in man (hCF). The ami-
no-terminal sequence of mCF has no homology with any
of the known proteins or cytokines [5,36]. The hCF puri-
¢ed from the sera of DHF patients, when inoculated into
mice increased capillary permeability and damage to the
blood-brain barrier indicating its role in pathogenicity
[36]. mCF and hCF appear to be pathogenesis-related
proteins, capable of reproducing DHF-like pathological
lesions in mice, such as increased capillary permeability,
cerebral edema, and blood leukocyte changes (reviewed in
[5,36,37]). During an extensive epidemic of DHF in North-
ern India during 1996, the presence of hCF was shown in
90% of the 333 cases with peak amounts in the most severe
cases of DHF grade IV [11]. Further, ex vivo culturing of
peripheral blood mononuclear cells of such cases showed
production of hCF by CD4 T cells but the number of
hCF-producing cells did not correlate with the severity of
the illness. The number of such cells may not indicate the
amount of hCF produced as it may depend upon factors
that trigger or down regulate the hCF-producing cells.
What regulates the over production of hCF in some pa-
tients is not known; is it the dose of the virus or some
humoral factor/cytokine or the genetic predisposition of
the host? We know that production of mCF is much
greater in inbred strains of mice than in the out-breds
(unpublished results). Furthermore, it is not known
whether hCF-producing cells are Th1 or Th2 or yet an-
other subset of CD4 T cells. It appears possible that
hCF-producing cells are either Th2-type or are regulated
by Th2-cytokines. [31,32]. The production of mCF/hCF
precedes the clinical illness in mice and man [30^33,36].
The DHF-like pathological lesions produced by mCF/
hCF can be prevented by pretreatment of mice with the
speci¢c antibodies [38]. This has led to active vaccination
of mice using mCF as antigen. The immunized mice were
protected against subsequent challenge with mCF. Chal-
lenge of such mice with a lethal intracerebral dose of DV
resulted in absence of clinical symptoms of the disease.
These studies suggest a vaccine strategy should be directed
against the primary cause of the disease (the cytokine)
rather than the infective agent. At present an e¡ective
vaccine against dengue is not yet available [39]. Similar
strategies are being successfully used in several diseases
using anti-TNF-K antibody therapy [40]. While the level
of TNF-K is increased in a variety of conditions, mCF/
hCF have the advantage of being present only in dengue.
We have shown that mCF is not produced during infec-
tion with an antigenically related Japanese encephalitis
virus an unrelated polio virus, coxsackie or ECHO viruses
and a number of bacteria and mitogens (reviewed in
[5,30]).
6. Proposed mechanism of pathogenesis in DHF
With the available data, we would like to propose a
mechanism that may explain the pathogenesis of DHF
(Fig. 1). DV replicates in macrophages and induces
quickly the CD4+ T cells to produce a unique cytokine,
hCF. hCF induces macrophages to produce free radicals,
nitrite, reactive oxygen and peroxynitrite [41,42]. The free
radicals, besides killing the target cells by apoptosis also
directly upregulate production of proin£ammatory cyto-
kines IL-1L, TNF-K, IL-8, and hydrogen peroxide in
macrophages. The change in relative levels of IL-12 and
TGF-L shifts a Th1-dominant response to a Th2-biased
response resulting in an exacerbation of dengue disease
and death of patients. The vascular permeability is in-
creased due to the combined e¡ect of histamine, free
radicals, proin£ammatory cytokines and the products
of the complement pathway etc. Thus the key player ap-
pears to be hCF, but what regulates its activity is not
known.
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